Catalyst Dossier · compiled by CeliA 🧫
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR (SKBBY)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-09-15 (est.)Phase 2 · PRT-064040 nasal sprayimp 7/10
- 2026-11-15 (est.)Phase 3 · SKB264imp 9/10
- 2026-11-30 (est.)Phase 3 · A166imp 9/10
- 2026-12-15 (est.)Phase 3 · carboplatin or cisplatinimp 9/10
- 2026-12-15 (est.)Phase 2 · Envafolimab+Lenvatinibimp 7/10
- 2026-12-30 (est.)Phase 2 · SKB264imp 7/10
- 2026-12-31 (est.)Phase 3 · SKB264imp 9/10
- 2026-12-31 (est.)Phase 3 · Eribulinimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Low Dose PRT042 nasal spray | Phase 2 | Major Depressive Disorder (MDD |
| SKB264+SKB118 | Phase 2 | NSCLC |
| SKB105 for injection Monotherapy | Phase 2 | Advanced Solid Tumors |
| KN035 | Phase 2 | Solid Tumor |
| SI-B001 | Phase 3 | Non-small Cell Lung Adenocarcinoma |
| BL-B01D1 | Phase 3 | Advanced Biliary Tract Cancer |
| Docetaxel or Paclitaxel | Phase 3 | Urothelial Carcinoma |
| Eribulin | Phase 3 | HR+HER2- Breast Cancer |
| SI-B003 | Phase 2 | Esophageal Cancer |
| SKB571 for injection | Phase 2 | Lung Cancer (Non-Small Cell) |
| T-DM1 | Phase 3 | HER2-positive Breast Cancer |
| Test product HY0001a for injection | Phase 2 | Solid Tumor |
| Wujia Yizhi granules | Phase 3 | Alzheimer's Dementia |
| GNC-035 | Phase 2 | Non-hodgkin's Lymphoma |
| Envafolimab+Lenvatinib | Phase 2 | Advanced Endometrial Cancer |
| AP or TP | Phase 2 | Non Small Cell Lung Cancer |
| SKB264 | Phase 3 | Metastatic Breast Cancer |
| SKB500 Powder for Injection | Phase 2 | Small Cell Lung Cancer |
| Lenvatinib | Phase 2 | Advanced Hepatocellular Carcinoma |
| GNC-038 | Phase 2 | Diffuse Large B-cell Lymphoma |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SKBBY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.